The latest trading day saw Boston Scientific (BSX) settling at $91.75, representing a -1.02% change from its previous close.
BSX builds momentum in PFA as FARAPULSE posts strong growth, and new trial results and expanded FDA labeling boost its AF treatment push.
Boston Scientific Corporation (BSX) Presents at Citi Annual Global Healthcare Conference 2025 Prepared Remarks Transcript
| Health Care Equipment & Supplies Industry | Healthcare Sector | Michael F. Mahoney CEO | XETRA Exchange | US1011371077 ISIN |
| US Country | 53,000 Employees | - Last Dividend | 6 Nov 2003 Last Split | 18 May 1992 IPO Date |
Boston Scientific Corporation is a global developer, manufacturer, and marketer of medical devices used in a variety of interventional medical specialties. Having begun its operations in 1979, the company has grown to serve a diverse range of medical needs through its two primary segments: MedSurg and Cardiovascular. With its headquarters in Marlborough, Massachusetts, Boston Scientific is committed to improving patient health by providing cutting-edge solutions that address complex medical conditions and enhance the quality of life for patients worldwide.